BRÈVE

sur BioNxt Solutions Inc. (isin : CA0909741062)

BioNxt Provides Update on Cladribine Program for Multiple Sclerosis

VANCOUVER, BC / ACCESSWIRE / September 26, 2024 / BioNxt Solutions Inc. ("BioNxt") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) has provided an update on its sublingual Cladribine drug formulation program aimed at treating Multiple Sclerosis (MS), a new patent for anticancer drug use in autoimmune neurodegenerative diseases, and recent investor relations activities.

BioNxt's sublingual Cladribine, targeting the MS market, offers benefits for patients with Dysphagia, common among MS sufferers. The company reported positive results from animal toxicity and pharmacokinetics studies earlier this year, with plans for a human bioequivalence study in early Q1 2025.

Furthermore, BioNxt announced a positive examination report from the European Patent Office for its sublingual delivery of anticancer drugs patent. The company plans to submit the patent in multiple jurisdictions, including the US, Canada, and China.

Additionally, BioNxt has confirmed the development of a sublingual drug delivery system for Myasthenia Gravis (MG), another condition where Dysphagia is prevalent. The company also outlined ongoing activities to engage consultants to manage investor relations and increase market liquidity.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de BioNxt Solutions Inc.